|
|
||||||||
1 Dept of Pulmonary Diseases, Turku University Hospital, Turku, 2 Dept of Physiology, Sleep Research Unit, Turku University, Turku, 3 Dept of Obstetrics and Gynaecology, Turku University Hospital, Turku, and 4 Dept of Clinical Neurophysiology, Satakunta Central Hospital, Pori, Finland
CORRESPONDENCE: T. Saaresranta, Dept of Pulmonary Diseases, Turku University Central Hospital, Kiinamyllynkatu 48, FIN-20520, Turku, Finland. Fax: 358 23133328
Keywords: medroxyprogesterone acetate, menopause, nasal continuous positive airway pressure, partial upper airway obstruction, sleep, sustained effect
Received: December 11, 2000
Accepted July 10, 2001
This work was supported by grants from the Finnish Sleep Research Society, The Finnish Anti-Tuberculosis Association Foundation, The Research Foundation for Pulmonary Diseases, The Väinö and Laina Kivi Foundation and The Turku University Foundation. O. Polo was supported by The Paulo Foundation.
The aim of the present study was to evaluate the degree and duration of respiratory stimulation caused by medroxyprogesterone acetate (MPA), and compare the effect of MPA to that of nasal continuous positive airway pressure (nCPAP) in sleep-disordered breathing.
Ten postmenopausal females with predominantly partial upper airway obstruction during sleep had an overnight sleep study at baseline, on the fourteenth day of treatment with MPA and after a 3-week washout period. Six subjects on nCPAP were also studied 3 months later.
At baseline, the overnight mean±sd end-tidal pressure of carbon dioxide (Pet,CO2) was 5.5±0.4 kPa the arterial oxygen saturation (Sa,O2) 93.0±1.2%, Sa,O2 nadir 80.0±6.7%, and frequency of oxygen desaturation
Medroxyprogesterone acetate at a daily dose of 60 mg improves ventilation in postmenopausal females with partial upper airway obstruction during sleep without compromising sleep. The ventilatory improvement is sustained for at least 3 weeks post-treatment. Medroxyprogesterone acetate was more efficient in decreasing the partial pressure of carbon dioxide but continuous positive airway pressure was superior in decreasing respiratory efforts.
4% (ODI4) per hour 2.2±1.3. MPA decreased Pet,CO2 by 0.8 kPa (14.5%, p<0.001). After washout, the mean Pet,CO2 remained at 0.5 kPa (9.1%, p<0.001) lower than at baseline. Sa,O2 did not change. Pet,CO2 was lower on MPA than on nCPAP (4.7±0.2 kPa versus 5.0±0.3 kPa; p=0.037) but Sa,O2 was similar. Apnoea/hypopnoea index tended to be lower on CPAP than on MPA.
This article has been cited by other articles:
![]() |
B. Buyse and the participants of working group 2 Treatment effects of sleep apnoea: where are we now? Eur. Respir. Rev., December 1, 2007; 16(106): 146 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Kravitz, I. Janssen, N. Santoro, J. T. Bromberger, M. Schocken, S. A. Everson-Rose, K. Karavolos, and L. H. Powell Relationship of Day-to-day Reproductive Hormone Levels to Sleep in Midlife Women Arch Intern Med, November 14, 2005; 165(20): 2370 - 2376. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saaresranta and O. Polo Sleep-disordered breathing and hormones Eur. Respir. J., July 1, 2003; 22(1): 161 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. White The Hormone Replacement Dilemma for the Pulmonologist Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1165 - 1166. [Full Text] [PDF] |
||||
![]() |
T. Young, L. Finn, D. Austin, and A. Peterson Menopausal Status and Sleep-disordered Breathing in the Wisconsin Sleep Cohort Study Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1181 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saaresranta, K. Irjala, and O. Polo Effect of medroxyprogesterone on arterial blood gases, leptin and neuropeptide Y in postmenopausal females Eur. Respir. J., December 1, 2002; 20(6): 1413 - 1418. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saaresranta and O. Polo Hormones and Breathing Chest, December 1, 2002; 122(6): 2165 - 2182. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |